Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ben Shin

Pain Medicine New York, NY Medical Doctor

NPI 1245616044 CMS profile 1385932

525 E 68Th St # F-1600, Fl 12, New York, NY 10065

Open in the dashboard

General payments

$17,196

44 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ben Shin of New York, NY is reported in the CMS Open Payments database as having received $17,196 across 44 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $285 6
2024 General $301 8
2023 General $531 9
2020 General $918 14
2019 General $15,161 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ben Shin
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Ben Shin were reported at $285. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Ben Shin Pain Medicine median Middle half National median
2019 $15,161 $409 $115–$1,311 $163
2020 $918 $214 $66–$666 $114
2021 $0 $299 $84–$899 $132
2022 $0 $335 $103–$1,149 $149
2023 $531 $376 $114–$1,228 $160
2024 $301 $387 $115–$1,173 $164
2025 $285 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $15,300 5 payments
  2. Medtronic, Inc. $621 15 payments
  3. Abbott Laboratories $570 11 payments
  4. MML US, Inc. $248 2 payments
  5. SPR Therapeutics, Inc $225 5 payments
  6. Nevro Corp. $149 4 payments
  7. Medtronic USA, Inc. $61 1 payment
  8. Biogen, Inc. $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $15,000 1 payment
  2. Food and Beverage $2,096 40 payments
  3. Education $74 1 payment
  4. Travel and Lodging $25 2 payments
Products named General payments · program years 2019–2025
  1. SPECTRA WAVEWRITER $15,000 1 payment
  2. Proclaim Family of SCS IPGs $532 9 payments
  3. INTELLIS ADAPTIVESTIM $353 9 payments
  4. ReActiv8 $248 2 payments
  5. INCEPTIV $246 5 payments
  6. SPRINT PNS System $225 5 payments
  7. GENERAL - PAIN MANAGEMENT $187 3 payments
  8. Senza Spinal Cord Stimulation System $149 4 payments
  9. SUPERION $113 1 payment
  10. INTELLIS $61 1 payment
  11. Other $53 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

420

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$2,707

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

0%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 158 $1,210
Baclofen Generic 143 $1,174
Meloxicam Generic 87 $136
Methylprednisolone Generic 17 $102
Pregabalin Generic 15 $84

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$268,874

Of which drugs: $19,203

Medicare patients

462

Average age 76

Services billed

6,138

274 women, 188 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 64%
Ischemic heart disease 34%
Osteoporosis 29%
Diabetes 26%
Depression 24%
Cancer 20%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 33 2,448 $17,257
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 55 257 $195
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 111 1,616 $144

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

44 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record